Clinical Trial RESULTS
The two tables below show which dose groups of AZD9977 had these medical problems:
Most Common Medical Problems in Part A of the Study
5 mg 25 mg
Placebo AZD9977 AZD9977 100 mg AZD9977 200 mg AZD9977
(Out of 16 (Out of 6 (Out of 6 (Out of 6 (Out of 5
Medical Problems participants) participants) participants) participants) participants)
1 participant 1 participant 1 participant 0 participants 1 participant
Dizziness
(6.3%) (16.7%) (16.7%) (0.0%) (20.0%)
0 participants 0 participants 0 participants 1 participants 0 participants
Back Pain
(0.0%) (0.0%) (0.0%) (16.7%) (0.0%)
Most Common Medical Problems in Part A of the Study (Continued)
800 mg 1200 mg
400 mg 800 mg AZD9977, AZD9977, AZD9977
AZD9977 AZD9977 split doses split doses Total
(Out of 6 (Out of 5 (Out of 6 (Out of 6 (Out of 46
Medical Problems participants) participants) participants) participants) participants)
0 participants 0 participants 0 participants 0 participant 3 participants
Dizziness
(0.0%) (0.0%) (0.0%) (0.00%) (6.5%)
1 participant 0 participants 0 participants 0 participants 2 participants
Back Pain
(16.7%) (0.0%) (0.0%) (0.0%) (4.3%)
What were the most common medical problems in Part B?
In Part B of the study, the only medical problem that happened in more than 1 participant was the
common cold. One out of 8 participants (12.5%) who took the capsule form and 1 out of 7 participants
(14.2%) who took the liquid form had the common cold. The table below shows how many
participants had medical problems in Part B of this study:
Medical Problems in Part B of the Study
Medical Capsule Liquid
Problems (Out of 8 participants) (Out of 7 participants)
1 participant 1 participant
Common cold
(12.5%) (14.2%)
How many participants in this study had serious medical problems?
A medical problem is considered serious when it is life-threatening, causes lasting problems
or a participant needs hospital care.
No participants had serious medical problems.
7